Oxalis Lab

Oxalis Lab is a French biotechnology company specializing in the development of small molecule therapeutics that selectively inhibit the translation of specific mRNAs involved in disease progression. Founded as a spin-off from the Institut Curie and Gustave Roussy, the company leverages deep expertise in RNA biology and protein synthesis regulation. Their primary focus is on oncology and inflammatory diseases, where they target the translation initiation machinery to block the production of oncogenic and pro-inflammatory proteins. By modulating translation rather than direct protein inhibition, Oxalis Lab aims to provide more effective treatments for patients with high unmet medical needs. The company's proprietary platform identifies specific mRNAs that are over-translated in pathological conditions, allowing for the design of highly selective inhibitors.